SCHEMBL3972075

SCHEMBL3972075

CCCCN(C)c1nc(-c2ccc(Br)cc2)nc2ccc(Cl)cc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 4/20 0.52
LATS1 O95835 1/20 0.51
LATS2 Q9NRM7 1/20 0.51
MAPT P10636 4/20 0.41
MAPK1 P28482 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
HTT P42858 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
FABP4 P15090 1/20 0.39
FABP5 Q01469 1/20 0.39
TP53 P04637 3/20 0.39
POLB P06746 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
LMNA P02545 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3975155 0.91 POLB (0.46) ADORA3LATS1LATS2MAPK1MEN1
SCHEMBL3978935 0.87 LATS1 (0.52) ADORA3LATS1LATS2MAPTMAPK1
SCHEMBL3974313 0.82 PDE5A (0.60) ADORA3MAPTMAPK1NPSR1MEN1
SCHEMBL3972107 0.81 LATS1 (0.50) LATS1LATS2MAPTMAPK1NPSR1
SCHEMBL3975242 0.78 RAD52 (0.45) LATS1LATS2MAPTMAPK1KMT2A
SCHEMBL3974635 0.77 ACP1 (0.58) ADORA3LATS1LATS2MAPTMAPK1
SCHEMBL3974463 0.76 HTR3A (0.48) ADORA3MAPTMAPK1NPSR1MEN1
SCHEMBL3977126 0.74 GBA1 (0.49) ADORA3MAPTMAPK1NPSR1MEN1
SCHEMBL3972071 0.74 ADORA3 (0.51) ADORA3MAPK1HTTKDM4ENPC1
SCHEMBL4857324 0.74 MAPT (0.66) LATS1LATS2MAPTMAPK1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547702-B2 4-amino-quinazolines ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2009-06-16 US disclosed
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents ORTHO-MCNEIL PHARMACEUTICALS, INC. 2006-01-26 US disclosed
WO-2004030672-A1 USE OF 4 AMINO-QUINAZOLINES AS ANTI CANCER AGENTS MERCK PATENT GMBH (DE) 2004-04-15 WO disclosed
CN-1474815-A 4-amino-quinazolines Ĭ��ר���ɷ����޹�˾ 2004-02-11 CN disclosed
EP-1318984-A1 4-AMINO-QUINAZOLINES MERCK PATENT GmbH (DE) 2003-06-18 EP disclosed
WO-2002024667-A1 4-AMINO-QUINAZOLINES MERCK PATENT GMBH (DE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents SERPINA3, APOL1, MGAT3 ADORA3 448/4885LATS1 4427/4885LATS2 4548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.